Altered kynurenine pathway metabolite levels in toddlers and preschool children with autism spectrum disorder

References

• Volkmar F, Siegel M, Woodbury-Smith M, et al. American Academy of C, Adolescent Psychiatry Committee on Quality I: practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2014;53(2):237–257.
   PubMed Web of Science ®Google Scholar
• Narzisi A, Posada M, Barbieri F, et al. Prevalence of autism spectrum disorder in a large Italian catchment area: a school-based population study within the asdeu project. Epidemiol Psychiatr Sci. 2020;29:1–10.
   Web of Science ®Google Scholar
• Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Surveill Summ. 2018;67:1–23.
   PubMed Web of Science ®Google Scholar
• Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res. 2017;10:1178646917691938.
   Web of Science ®Google Scholar
• Ruddick JP, Evans AK, Nutt DJ, et al. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med. 2006;8(20):1–27.
   PubMedGoogle Scholar
• Dantzer R, O'Connor JC, Lawson MA, et al. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36(3):426–436.
   PubMed Web of Science ®Google Scholar
• Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (trycat) pathway. Psychiatry Res. 2012;196(2-3):243–249.
   PubMed Web of Science ®Google Scholar
• Songtachalert T, Roomruangwong C, Carvalho AF, et al. Anxiety disorders: sex differences in serotonin and tryptophan metabolism. Curr Top Med Chem. 2018;18(19):1704–1715.
   PubMed Web of Science ®Google Scholar
• Parasram K. Phytochemical treatments target kynurenine pathway induced oxidative stress. Redox Rep. 2018;23(1):25–28.
   PubMed Web of Science ®Google Scholar
• Bryn V, Verkerk R, Skjeldal OH, et al. Kynurenine pathway in autism spectrum disorders in children. Neuropsychobiology. 2017;76(2):82–88.
   PubMed Web of Science ®Google Scholar
• Okuda S, Nishiyama N, Saito H, et al. 3-hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998;70(1):299–307.
   PubMed Web of Science ®Google Scholar
• Lee WS, Lee SM, Kim MK, et al. The tryptophan metabolite 3-hydroxyanthranilic acid suppresses t cell responses by inhibiting dendritic cell activation. Int Immunopharmacol. 2013;17(3):721–726.
   PubMed Web of Science ®Google Scholar
• Krause D, Suh HS, Tarassishin L, et al. The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. Am J Pathol. 2011;179(3):1360–1372.
   PubMed Web of Science ®Google Scholar
• Tuboly G, Tar L, Bohar Z, et al. The inimitable kynurenic acid: the roles of different ionotropic receptors in the action of kynurenic acid at a spinal level. Brain Res Bull. 2015;112:52–60.
   PubMed Web of Science ®Google Scholar
• Hilmas C, Pereira EF, Alkondon M, et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21(19):7463–7473.
   PubMed Web of Science ®Google Scholar
• Klein C, Patte-Mensah C, Taleb O, et al. The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction. Neuropharmacology. 2013;70:254–260.
   PubMed Web of Science ®Google Scholar
• Boccuto L, Chen CF, Pittman AR, et al. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism. 2013;4(1):16.
   PubMedGoogle Scholar
• Lim CK, Essa MM, de Paula Martins R, et al. Altered kynurenine pathway metabolism in autism: implication for immune-induced glutamatergic activity. Autism Res. 2016;9(6):621–631.
   PubMed Web of Science ®Google Scholar
• Ormstad H, Bryn V, Verkerk R, et al. Serum tryptophan, tryptophan catabolites and brain-derived neurotrophic factor in subgroups of youngsters with autism spectrum disorders. CNS Neurol Disord Drug Targets. 2018;17(8):626–639.
   PubMed Web of Science ®Google Scholar
• Gal EM, Sherman AD. L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5(3):223–239.
   PubMed Web of Science ®Google Scholar
• Curzon G. Relationships between plasma, CSF and brain tryptophan. J Neural Transm. 1979;15 Suppl:81–92.
   Google Scholar
• Su Maw S, Haga C. Effectiveness of cognitive, developmental, and behavioural interventions for autism spectrum disorder in preschool-aged children: a systematic review and meta-analysis. Heliyon. 2018;4(9):e00763.
   PubMed Web of Science ®Google Scholar
• Sorgdrager FJH, Vermeiren Y, Van Faassen M, et al. Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease. J Neurochemistry. 2019;151(5):656–668.
   PubMed Web of Science ®Google Scholar
• Kepplinger B, Baran H, Kainz A, et al. Age-related increase of kynurenic acid in human cerebrospinal fluid – IgG and beta2-microglobulin changes. Neurosignals. 2005;14(3):126–135.
   PubMedGoogle Scholar
• Ulvik A, Theofylaktopoulou D, Midttun O, et al. Substrate product ratios of enzymes in the kynurenine pathway measured in plasma as indicators of functional vitamin B-6 status. Am J Clin Nutr. 2013;98(4):934–940.
   PubMed Web of Science ®Google Scholar
• Lovelace MD, Varney B, Sundaram G, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology. 2017;112(Pt B):373–388.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington, VA: American Psychiatric Pub; 2013.
   Google Scholar
• Schopler E, Reichler RJ, DeVellis RF, et al. Toward objective classification of childhood autism: childhood autism rating scale (CARS). J Autism Dev Disord. 1980;10(1):91–103.
   PubMed Web of Science ®Google Scholar
• Krug DA, Arick J, Almond P. Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior. J Child Psychol Psychiatry. 1980;21(3):221–229.
   PubMed Web of Science ®Google Scholar
• Sucuoglu B, Oktem F, Akkok F, et al. A study about childhood autism scales. Psychiatr Psychol Psychopharmacol (3P) J. 1996;4:116–121.
   Google Scholar
• Yilmaz-Irmak T, Tekinsav-Sutcu S, Aydin A, et al. An investigation of validity and reliability of autism behavior checklist (ABC). Turk J Child Adolesc Mental Health. 2007;14:13–23.
   Google Scholar
• Groer M, Fuchs D, Duffy A, et al. Associations among obesity, inflammation, and tryptophan catabolism in pregnancy. Biol Res Nurs. 2018;20(3):284–291.
   PubMed Web of Science ®Google Scholar
• Tong Q, Song J, Yang G, et al. Simultaneous determination of tryptophan, kynurenine, kynurenic acid, xanthurenic acid and 5-hydroxytryptamine in human plasma by LC-MS/MS and its application to acute myocardial infarction monitoring. Biomed Chromatogr. 2018;32:e4156.
   Google Scholar
• Banerjee J, Alkondon M, Albuquerque EX. Kynurenic acid inhibits glutamatergic transmission to ca1 pyramidal neurons via α7 nAChR-dependent and -independent mechanisms. Biochem Pharmacol. 2012;84(8):1078–1087.
   PubMed Web of Science ®Google Scholar
• Shepard PD, Joy B, Clerkin L, et al. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology. 2003;28(8):1454–1462.
   PubMed Web of Science ®Google Scholar
• Reynolds S, Millette A, Devine DP. Sensory and motor characterization in the postnatal valproate rat model of autism. Dev Neurosci. 2012;34(2-3):258–267.
   PubMed Web of Science ®Google Scholar
• Rodier PM, Ingram JL, Tisdale B, et al. Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J Comp Neurol. 1996;370(2):247–261.
   PubMed Web of Science ®Google Scholar
• Ameele S, Nuijs AL, Lai FY, et al. A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder. Bipolar Disord. 2020;22(1):59–69., doi: https://doi.org/10.1111/bdi.12814.
   PubMedGoogle Scholar
• Condray R, Dougherty GG, Keshavan MS, Jr, et al. 3-hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol. 2011;14(6):756–767.
   PubMed Web of Science ®Google Scholar
• Reyes-Ocampo J, Ramirez-Ortega D, Cervantes GI, Pineda, et al. Mitochondrial dysfunction related to cell damage induced by 3-hydroxykynurenine and 3-hydroxyanthranilic acid: non-dependent-effect of early reactive oxygen species production. Neurotoxicology. 2015;50:81–91.
   PubMed Web of Science ®Google Scholar
• Teshigawara T, Mouri A, Kubo H, et al. Changes in tryptophan metabolism during pregnancy and postpartum periods: potential involvement in postpartum depressive symptoms. J Affect Disord. 2019;255:168–176.
   PubMed Web of Science ®Google Scholar
• Miller CL, Llenos IC, Cwik M, Walkup J, et al. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int. 2008;52(6):1297–1303.
   PubMed Web of Science ®Google Scholar
• Aarsland TI, Landaas ET, Hegvik TA, et al. Serum concentrations of kynurenines in adult patients with attention-deficit hyperactivity disorder (ADHD): a case-control study. Behav Brain Funct. 2015;11:36.
   PubMed Web of Science ®Google Scholar
• Darlington LG, Forrest CM, Mackay GM, et al. On the biological importance of the 3-hydroxyanthranilic acid: anthranilic acid ratio. Int J Tryptophan Res. 2010;3:51–59.
   PubMedGoogle Scholar
• Sweeten T, Taylor MW, Milton W, et al. Plasma kynurenine levels in autistic disorder. J Dev Phys Disabil. 2006;18(4):419–426.
   Web of Science ®Google Scholar
• Swartz KJ, During MJ, Freese A, et al. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci. 1990;10(9):2965–2973.
   PubMed Web of Science ®Google Scholar
• Lamy M, Pedapati EV, Dominick KL, et al. Recent advances in the pharmacological management of behavioral disturbances associated with autism spectrum disorder in children and adolescents. Paediatr Drugs. 2020;22(5):473–483.
   PubMed Web of Science ®Google Scholar
• Maciejak P, Szyndler J, Turzyńska D, et al. The kynurenine pathway: a missing piece in the puzzle of valproate action? Neuroscience. 2013;234:135–145.
   PubMed Web of Science ®Google Scholar
• Ceresoli-Borroni G, Rassoulpour A, Wu HQ, et al. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm (Vienna)). 2006;113(10):1355–1365.
   PubMed Web of Science ®Google Scholar
• Qiu W, Duarte-Guterman P, Eid RS, et al. Postpartum fluoxetine increased maternal inflammatory signalling and decreased tryptophan metabolism: clues for efficacy. Neuropharmacology. 2020;175:108174.
   PubMed Web of Science ®Google Scholar
• Réus GZ, Jansen K, Titus S, et al. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies. J Psychiatr Res. 2015;68:316–328.
   PubMed Web of Science ®Google Scholar
• Réus GZ, Becker IRT, Scaini G, et al. The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:55–63.
   PubMed Web of Science ®Google Scholar